Case Law

Case Law, EPO, Exceptions to patentability, France, FRAND, Injunction, Inventive step, IP Management, Litigation, Novelty, Patents, SEP

(Dhenne Avocats)/

In the first part of this interview (see here), I already mentioned some of the preconceived ideas about French Courts, which makes France almost systematically considered as one of the last territory to litigate: jurisdictions would be anti-patentee, slow, unable to order preliminary injunctions, even not “specialized”. The Cross-Examination Part I of Mrs. Nathalie Sabotier…

Case Law, EPC, EPO Decision, Patents

(Dhenne Avocats)/ /9 Comments

G 1/19, which admits the patentability of a computer-implemented simulation, was the second opportunity for the Enlarged Board of Appeal to rule on the assessment of the patentability of computer-implemented inventions. Did it take advantage of this One More Chance or was it only One More Time? At any rate, here, I will only briefly comment…

Case Law, evidence, France, IP Management, Litigation, Patents, Procedure

(Dhenne Avocats)/

It’s an understatement to say that it’s not always very easy to be a French patent litigator in a transnational litigation, in any case a good dose of humor is needed: how many jokes have I heard about our jurisdictional system? Then you have to accept that France is almost systematically considered as the territory…

Case Law, evidence, France, Infringement, Injunction, IP Management, Litigation, Patents, Procedure

(Dhenne Avocats)/

It’s an understatement to say that it’s not easy to be a French patent litigator in transnational litigation, in any case a good dose of humor is needed: how many jokes have I heard about our jurisdictional system? Then you have to accept that France is almost systematically considered as the territory at the bottom…

Case Law, Infringement, Pharma, United States of America

(Gibson, Dunn & Crutcher LLP) and , (Ropes & Gray LLP)/

Biologic drugs, many of which are antibodies, represent an increasing share of the pharmaceutical market. In recent years, numerous broad functional patent claims directed at therapeutic antibodies have come under attack for failing to satisfy the written description and enablement requirements. The proper scope of these requirements has divided the biopharmaceutical industry. In its latest…

Case Law, FRAND, India, SEP

(Anand and Anand)/

Can natural justice outweigh statute, contractual confidentiality obligations and industry practice? Recently, the High Court of Delhi passed a decision in the heated FRAND dispute between InterDigital and Xiaomi concerning confidentiality clubs [1]. Read part 1 of this blog. 3. Key errors in the order of the Court I. Confidentiality concerns of InterDigital and its…

Case Law, FRAND, India, SEP

(Anand and Anand)/

Can natural justice outweigh statute, contractual confidentiality obligations and industry practice? Recently, the High Court of Delhi passed a decision in the heated FRAND dispute between InterDigital and Xiaomi concerning confidentiality clubs. [1] The Court held that that Xiaomi’s employees must necessarily have access to InterDigital’s third party patent license agreements, so that Xiaomi may…

(Indirect) infringement, Case Law, Equivalents, evidence, Kluwer Patent Cases, Legislation, Litigation, Patents, Pharma, Pharmaceutical patent, Prior art, Procedure, Scope of protection, Sufficiency of disclosure, United Kingdom, Validity

(Bristows)/ /1 Comment

As reported in last week’s post, on 20 January 2021 Birss J handed down what may be his last first instance decision before his elevation to the Court of Appeal.  The first post on the judgment considered the issues of identifying the skilled person, insufficiency and infringement.  This second part considers the decision relating to…